Most Read Articles
Stephen Padilla, 04 Sep 2019
Use of sodium glucose cotransporter 2 (SGLT2), as compared with dipeptidyl peptidase 4 (DPP4), inhibitors appears to reduce the risk of heart failure and any-cause death without major cardiovascular events in the primary intention-to-treat analysis, according to a study.
Pearl Toh, 04 Sep 2019
More intensive LDL-lowering by adding ezetimibe to simvastatin in elderly individuals aged ≥75 years significantly reduced recurrent cardiovascular (CV) events without raising safety issues compared with simvastatin alone, a secondary analysis of the IMPROVE-IT* has shown.
27 Aug 2019
A once-weekly regimen of 25 mg trelagliptin is effective and safe for type 2 diabetes mellitus (T2DM) patients with severe renal impairment or end-stage renal disease, reports a new study.
Elvira Manzano, 4 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

PPI effectively attenuates acid-related dyspepsia

29 Jun 2019

Monotherapy with a proton pump inhibitor appears to be effective in the treatment of functional dyspepsia (FD) symptoms associated with gastro-oesophageal reflux disease (GERD), according to a study.

The study included 233 patients (mean age, 56.5 years; 58 percent male; mean body mass index, 23.7 kg/m2) with FD and GERD, among whom 40 had mild, 151 had moderate and 42 had severe GERD symptoms. All patients were given PPI treatment for 4 weeks after endoscopy, and the severity of the symptoms and responses to treatment were evaluated prior to and after 4 weeks of treatment using the Gastroesophageal Reflux and Dyspepsia Therapeutic Efficacy and Satisfaction Test (GERD-TEST).

In the entire population, the pretreatment scores for the symptoms recorded were as follows: 3.7 for GERD-symptom subscale (SS), 3.3 for FD-SS, 3.6 for FD-epigastric pain syndrome symptom, and 3.0 for FD-postprandial distress-SS.

Analysis of the pretreatment scores for each symptom showed that a higher GERD-SS score was significantly associated with higher scores on any kind of FD score.

Furthermore, 4 weeks of PPI treatment led to a significant reduction in any of GERD/FD symptoms. Changes in the score for each symptom were markedly greater in the group of patients with more severe GERD-SS.

In light of the present data, PPI monotherapy may be considered the treatment of choice in patients with FD and more severe GERD symptom, researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 04 Sep 2019
Use of sodium glucose cotransporter 2 (SGLT2), as compared with dipeptidyl peptidase 4 (DPP4), inhibitors appears to reduce the risk of heart failure and any-cause death without major cardiovascular events in the primary intention-to-treat analysis, according to a study.
Pearl Toh, 04 Sep 2019
More intensive LDL-lowering by adding ezetimibe to simvastatin in elderly individuals aged ≥75 years significantly reduced recurrent cardiovascular (CV) events without raising safety issues compared with simvastatin alone, a secondary analysis of the IMPROVE-IT* has shown.
27 Aug 2019
A once-weekly regimen of 25 mg trelagliptin is effective and safe for type 2 diabetes mellitus (T2DM) patients with severe renal impairment or end-stage renal disease, reports a new study.
Elvira Manzano, 4 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.